about
Trial watch - inhibiting PARP enzymes for anticancer therapyDNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of CancerBeyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid TumorsMantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agentsUpdate on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatmentPhase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma"Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitorsPhase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors.ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition.Phenothiazine Inhibitors of TLKs Affect Double-Strand Break Repair and DNA Damage Response Recovery and Potentiate Tumor Killing with Radiomimetic Therapy.Eugenol triggers apoptosis in breast cancer cells through E2F1/survivin down-regulation.PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitro hepatocellular carcinoma models.KIFC1 is a novel potential therapeutic target for breast cancer.DNA repair in cancer: emerging targets for personalized therapy.Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.Reverse the Resistance to PARP Inhibitors.PARP inhibitors in cancer therapy: an update.Resistance to PARP-Inhibitors in Cancer Therapy.PARP inhibitors: polypharmacology versus selective inhibition.Development of anticancer drugs based on the hallmarks of tumor cells.PARP inhibitorsEffects of hyperthermia on DNA repair pathways: one treatment to inhibit them all.Generation of small molecules to interfere with regulated necrosis.A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.Molecular approaches to potentiate cisplatin responsiveness in carcinoma therapeutics.Identification of evolutionarily conserved DNA damage response genes that alter sensitivity to cisplatin.Nanotherapy for Cancer: Targeting and Multifunctionality in the Future of Cancer Therapies.PARP inhibitors and IR join forces to strike glioblastoma-initiating cells.Niraparib in ovarian cancer: results to date and clinical potential.Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699).Phase I study of veliparib in combination with gemcitabine.Quantitative Analysis of NAD Synthesis-Breakdown Fluxes.The multifunctional protein YB-1 potentiates PARP1 activity and decreases the efficiency of PARP1 inhibitors.Targeted Tumor Therapy Remixed-An Update on the Use of Small-Molecule Drugs in Combination Therapies.
P2860
Q26745673-47794A6C-071E-40ED-BA1B-A8D3F816587EQ26776513-EDEC003C-E076-4B19-935D-3C02DDB56783Q26852274-07B67131-0A81-453A-A153-058DB95BC206Q28075606-2493EC9D-A3BF-4182-A34E-2B56DE9834F4Q28075761-E7ACA9E6-19E1-4629-BF8C-EC82C754ACACQ33426556-208F7A26-158F-405A-A3FC-3584A110F9D7Q33618910-9314B446-5E57-4A86-8722-C0788AA9C18FQ33954553-EE435965-EF8D-4F49-A937-95F9ED7E7D28Q34249365-0C59AF17-781D-4D64-89AF-F4E59FE6E9D5Q34942420-1525D786-6ED2-4F88-A3CE-D0DE81A564F1Q35065451-1B8CCBC3-B04D-4A63-B557-16D4805C7929Q35228413-43BECF68-ED71-41BF-B8C2-AB627BF0789DQ36211466-8643A554-714D-4C7C-A269-2DF56477D05AQ37600799-215ABEE9-17E8-4B28-AB93-99BA2A3246EEQ37601722-DF738C3F-E53C-4128-B906-9825B63F11D1Q37675896-47A2E5BC-6610-42C8-857E-3CCC5AFBDC27Q38078993-EB32C938-EC11-4585-A2CE-FE3B148D6D30Q38085600-BBFABF06-D07A-4930-9D43-A4B674D92499Q38100299-BC06CD9C-00D6-4DFB-B5CC-8E439CA79D5CQ38182491-867A86C7-F6B3-4049-AD0E-3FA5C0537854Q38326336-ABBBA2AB-1DF6-46C4-8A94-BEC52353B693Q38561332-023359AB-9D24-4E92-82F8-DDB1033405A4Q38799144-848E7BE1-56EE-49FB-A442-5451505F0DA8Q38811820-A4F5522C-B152-497C-A39B-846B7DCEB058Q39006252-AED97BE6-4558-41CD-BF35-751ADB883EEDQ39433258-A401DF03-51CA-4303-A592-63976BFD04DEQ42292342-18240F9B-7435-4266-B994-629B9DDF9A65Q42562347-74654E59-B595-4F59-AA65-7F2E16592A2BQ42744048-9EB533D9-31B0-4433-B036-8765391BCC53Q42820765-CEA3AD5C-39E5-4B00-A846-A87EA8B6DCCAQ44226295-658119BD-F5B3-4D4D-8521-09914456AF0AQ47100777-9291A4FA-7CE9-4FA2-B03B-AB81E140CF3AQ52568842-6FED5F1A-FDDE-40FD-80A5-BB22E7406313Q54935812-4EF514E9-0785-4FFD-B80C-6C4D15E0C87BQ54978342-CD876A1F-A37F-45B6-8078-D5CDA54CE219
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Role of PARP inhibitors in cancer biology and therapy
@ast
Role of PARP inhibitors in cancer biology and therapy
@en
type
label
Role of PARP inhibitors in cancer biology and therapy
@ast
Role of PARP inhibitors in cancer biology and therapy
@en
prefLabel
Role of PARP inhibitors in cancer biology and therapy
@ast
Role of PARP inhibitors in cancer biology and therapy
@en
P2093
P2860
P1476
Role of PARP inhibitors in cancer biology and therapy
@en
P2093
P2860
P304
P356
10.2174/092986712802002464
P577
2012-01-01T00:00:00Z